Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group

Heske CM, Chi YY, Venkatramani R, Li M, Arnold MA, Dasgupta R, Hiniker SM, Hawkins DS, Mascarenhas L. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Cancer. 2021 Mar 15;127(6):946-956. doi: 10.1002/cncr.33334. Epub 2020 Nov 20. PubMed PMID: 33216382; PubMed Central PMCID: PMC8601034.

The aim of this analysis was to evaluate the clinical factors influencing survival outcomes in patients with localized (clinical group I-III) FOXO1 fusion positive rhabdomyosarcoma (RMS). Patients with confirmed FOXO1 fusion positive RMS who were enrolled on three completed clinical trials for localized RMS were included in the analytic cohort. Outcomes were analyzed using the Kaplan-Meier method to estimate event-free survival (EFS) and overall survival (OS), and the curves were compared using the log-rank test. A Cox proportional hazards regression model was used to perform multivariate analysis of prognostic factors that were significant in the univariate analysis.